Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 18c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.59), $0.18 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance